Stereotactic body radiotherapy offers survival advantage in inoperable NSCLC

  • Lung Cancer

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Stereotactic body radiotherapy (SBRT) offered significantly better OS than percutaneous image-guided local tumor ablation (LTA) in patients with inoperable early-stage NSCLC.

Why this matters

  • This study contradicts previous research that found no significant difference in survival with SBRT vs LTA.

Study design

  • 15,792 patients with inoperable early-stage NSCLC from the National Cancer Database who received SBRT (n=14,651) or LTA (n=1141).
  • Median follow-up, 26.2 months.
  • Funding: NIH.

Key results

  • SBRT offered a lower mortality risk compared with LTA in the unadjusted cohort (HR, 0.86; P<.001 and after propensity score weighting p=".002).</li">
  • Adjusted rates of OS for SBRT vs LTA, respectively:
    • 1 year: 87.5% vs 83.5%.
    • 2 years: 68.0% vs 63.0%.
    • 3 years: 52.2% vs 45.9%.
    • 5 years: 31.0% vs 26.2%.
  • In the propensity score-weighted group, SBRT offered lower mortality risk than LTA for tumor sizes >2.0 cm (HR, 0.72; P<.001 but there was no significant difference between sbrt and lta for tumor sizes cm.>

Limitations

  • Retrospective design.